Kabazitaksel Fresenius Kabi (Cabazitaxel)

• Kabazitaksel is a taxane chemotherapy used in the treatment pathway of advanced prostate cancer.
• Metastatic castration‑resistant prostate cancer: provides a therapeutic option after docetaxel failure, improving disease control and overall survival.

• Cabazitaxel binds to the β‑tubulin subunit of microtubules, promoting polymerization and stabilizing the microtubule network. This prevents depolymerization, disrupts mitotic spindle formation, arrests cell division in the G2/M phase, and triggers apoptotic pathways in rapidly dividing cancer cells.

Cabazitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Fatigue: persistent tiredness affecting daily activities.
• Anemia: lowered red blood cells causing weakness.
• Nausea and vomiting: gastrointestinal upset.
• Diarrhea: loose stools that may lead to dehydration.
• Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Life‑threatening infections: sepsis or opportunistic infections.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Peripheral neuropathy: numbness or tingling in extremities.
• Cardiac events: arrhythmias or myocardial ischemia.

• Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.
• Monitor blood counts: perform regular CBC to detect neutropenia.
• Assess liver function: evaluate hepatic enzymes as cabazitaxel is hepatically cleared.
• Evaluate for hypersensitivity: observe for infusion‑related reactions during administration.
• Avoid in severe infection: postpone dosing until infection resolves.
• Use with caution in the elderly: consider dose adjustments based on tolerance.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise cabazitaxel plasma levels.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Concurrent myelosuppressive agents: increase risk of severe neutropenia.

Moderate Interactions (Monitor Closely)

• P‑glycoprotein inhibitors (e.g., verapamil): may modestly increase exposure.
• Anticoagulants (e.g., warfarin): heightened bleeding risk due to platelet effects.
• CYP2C8 substrates (e.g., paclitaxel): potential additive toxicity.